ASSESSMENT OF NEED FOR CONTINUED ORAL THERAPY IN DIABETICS

[1] REMISSION IN DIABETES [J]. BRITISH MEDICAL JOURNAL, 1959, 2 (OCT17) : 731 - 734

[2] BLOOM A, 1969, POSTGRADUATE MEDIC S

[3] IS USE OF SULPHONYLUREA DERIVATIVES IN TREATMENT OF DIABETES MELLITUS DANGEROUS [J]. DIABETOLOGIA, 1971, 7 (04) : 237 - &

[4] TOLBUTAMIDE IN DIABETES - SOME CLINICAL AND BIOCHEMICAL STUDIES [J]. BRITISH MEDICAL JOURNAL, 1957, 2 (AUG10) : 327 - 331

[5] KEEN H, 1965, LANCET, V2, P505

[6] KEEN H, 1970, ATHEROSCLEROSIS, P435

[7] MULLER R, 1969, HORMONE METABOLIS S1, V178, P88

[8] PASSIKIVI J, 1970, ACTA MEDICA SCA S507

[9] 1971, J AM MED ASS, V217, P777

[10] 1971, LANCET, V1, P171

[1] REMISSION IN DIABETES [J]. BRITISH MEDICAL JOURNAL, 1959, 2 (OCT17) : 731 - 734

[2] BLOOM A, 1969, POSTGRADUATE MEDIC S

[3] IS USE OF SULPHONYLUREA DERIVATIVES IN TREATMENT OF DIABETES MELLITUS DANGEROUS [J]. DIABETOLOGIA, 1971, 7 (04) : 237 - &

[4] TOLBUTAMIDE IN DIABETES - SOME CLINICAL AND BIOCHEMICAL STUDIES [J]. BRITISH MEDICAL JOURNAL, 1957, 2 (AUG10) : 327 - 331

[5] KEEN H, 1965, LANCET, V2, P505

[6] KEEN H, 1970, ATHEROSCLEROSIS, P435

[7] MULLER R, 1969, HORMONE METABOLIS S1, V178, P88

[8] PASSIKIVI J, 1970, ACTA MEDICA SCA S507

[9] 1971, J AM MED ASS, V217, P777

[10] 1971, LANCET, V1, P171